A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can ...

The pivotal Phase 3 trial for Cylembio® in advanced melanoma showed clinical improvement in progression free survival, but missed its primary endpoint for statistical significance (p=0.056; threshold ...

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

Pyxis Oncology anticipates having preliminary data from the Phase 1/2 combination study of MICVO in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in R/M HNSCC and other ...

GAAP revenue fell sharply to $6,550 in Q2 2025, GAAP revenue was $6,550, below the $7.0 million estimate, largely due to a suspended licensing agreement. Net loss (GAAP) improved dramatically to $1.9 ...

Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...

The trial tests BNT113, a biological treatment administered via IV injection, in combination with pembrolizumab, an IV infusion, to enhance therapeutic outcomes for patients with specific head and ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc., in collaboration with Merck Sharp & Dohme LLC, is conducting ...